Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's flagship solution, Genio, uses hypoglossal nerve stimulation, an alternative to CPAP therapy. With Genio, Nyxoah offers a comfortable and elegant treatment alternative that allows patients suffering from obstructive sleep apnea to enjoy life to the fullest.
Major Shareholders
37.87%Other
15.05%Cochlear Investments Pty Ltd
10.62%Robert Taub (incl. Robelga SRL and BMI Estate)
8.02%Vestal Point Capital
7.86%TOGETHER Partnership
7.85%Coöperatieve Gilde Healthcare III Sub-Holding U.A. and Coöperatieve Gilde Healthcare III Sub-Holding 2 U.A
4.62%ResMed Inc.
4.54%FMR LLC
3.59%Jürgen Hambrecht (incl. JH Capital GmbH)
The chart illustrates Nyxoah’s major shareholders (on an undiluted basis), based on transparency notifications received, recordings in the company’s share register, and the current denominator.